126 articles · page 6 of 11
No, my site did not get overrun by the pharmaceutical pushers that like to submit "advice" in the comments section. The title is referring to entity size (i.e., undiscounted, small, or micro). This posts will compare the three entity types on…
Below is an animated visualization of the subject matter eligibility 101 roller coaster that patent prosecutors and examiners have been on over the past 5 years. The visualization (interactive version available here , registration required) looks at…
Last Wednesday, we released our Patent Prosecution Intelligence Report for 2019 , where we have ranked the top 1,000 most active and best performing patent firms as well as patent owners (companies, universities, etc.). For this study, we looked at 2.2…
Hikma Pharms. and West-Ward Pharms petition for cert. to reverse the Fed. Cir.’s decision in Vanda v. West-Ward that methods of medical treatment are patentable. The Supreme Court’s now-infamous Mayo decision, invalidated claims to a method for…
A few weeks ago we published an article ( Patexia Insight 54 ), explaining why patent prosecution is becoming commoditized and why some of the AM LAW 100 are clearly abandoning their patent prosecution practices in favor of more profitable work. This…
Subcommittee to Tackle 101? Late last week, the Senate Judiciary Committee announced the formation of an Intellectual Property (IP) Subcommittee. The Senate Judiciary has not had an active IP Subcommittee for decades (unlike the House). Senators Thom…
In my last post, I discussed the Supreme Court’s opinion in Helsinn Healthcare v. Teva Pharms ., holding Helsinn’s patent on a drug was invalid on the basis that Helsinn’s semi-secret sale of the drug to a marketing partner triggered the…
As we prepare to release our first Patent Prosecution Intelligence Report , we have been hearing from many of practitioners that it is getting much harder to run a profitable practice these days, if they are only doing patent prosecution. This week, we…
On January 7th, the Patent Office released proposed revised s. 101 eligibility examination guidelines for public comment. The proposed Guidelines would supersede MPEP 2016.04(II), the section that controls the analysis conducted at step 2A of the…
In his remarks presented at the recent 10th Annual Patent Law & Policy Conference at Georgetown University Law School, USPTO Director Andrei Iancu outlined the analytical framework for the new, eagerly awaited, PTO Guidance on patent eligible subject…
A September 6th post by Dennis Crouch at PatentlyO (“ A Mixture of Known Compounds is Unpatentable without a Transformation “) led me to a closer reading of the cert. petition filed in Bhagat v. Iancu, (Case No. 18-277) an appeal from In re…
On July 13, 2018, the Federal Circuit decided Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC , affirming the Patent Trial and Appeal Board (PTAB)’s finding of invalidity of certain claims of seven Orange Book-listed patents for Xyrem®.…
